The Chinese Society of Clinical Oncology recommends tests for EGFR mutations as well as ALK and ROS1 fusion (category 1) in non-squamous NSCLC and next-generation sequencing to detect all clinically meaningful mutations (category 2) (2). This evidence concerns the gene ALK and non-small cell lung carcinoma.